Li Kang Biomedical Co., Ltd. (TPEX:6242)

Li Kang Biomedical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	60.02	42.93	64.95	111.84	132.01	101.36
Short-Term Investments	102.31	132.28	373.6	173.53	117.5	62.5
Trading Asset Securities	15.89	15.02	15.86	15.66	13.92	11.89
Cash & Short-Term Investments	178.22	190.22	454.4	301.02	263.43	175.75
Cash Growth	-48.69%	-58.14%	50.95%	14.27%	49.89%	-20.33%
Accounts Receivable	8.47	9.33	9.51	9.27	10.18	8.08
Receivables	8.47	9.33	9.51	9.27	10.18	8.08
Inventory	59.34	45.79	45.08	41.59	33.65	31.13
Prepaid Expenses	-	-	-	-	2.03	1.27
Other Current Assets	5.7	7.72	3.71	3.8	-	-
Total Current Assets	251.72	253.07	512.71	355.68	309.29	216.23
Property, Plant & Equipment	787.47	742.25	420.49	365.63	276.68	362.41
Long-Term Investments	14.76	14.73	19.38	20.88	25.38	26.04
Other Intangible Assets	0.73	0.78	1.93	1.08	1.68	0.24
Long-Term Deferred Tax Assets	0.42	0.52	0.61	0.52	-	0.1
Other Long-Term Assets	82.92	81.73	80.5	83.21	75.81	11.06
Total Assets	1,138	1,093	1,036	827.01	688.84	616.07

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	59.11	43.23	35.92	27.96	43.9	29.46
Accrued Expenses	29.07	36.24	37.55	43.32	39.54	30.99
Short-Term Debt	70	70	-	-	-	-
Current Portion of Long-Term Debt	-	-	5.36	3.65	-	8.88
Current Portion of Leases	2.84	2.81	0.9	-	-	-
Current Income Taxes Payable	9.18	9.61	7.46	28.67	28.54	12.09
Other Current Liabilities	71.09	6.59	6.86	6.08	6.63	6.92
Total Current Liabilities	241.29	168.48	94.05	109.69	118.61	88.34
Long-Term Debt	-	-	29.64	31.35	-	24.59
Long-Term Leases	53.72	53.21	56.02	55.84	-	-
Long-Term Deferred Tax Liabilities	0.15	0.13	0.22	0.09	0.09	-
Other Long-Term Liabilities	-	-	-	-	-	11.14
Total Liabilities	295.17	221.82	179.93	196.97	118.7	124.07

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	318.07	318.07	318.07	268.07	233.1	222
Additional Paid-In Capital	213.39	213.39	213.39	33.75	33.72	33.72
Retained Earnings	328.35	356.77	336.56	339.05	309.64	241.95
Comprehensive Income & Other	-16.95	-16.98	-12.33	-10.83	-6.33	-5.67
Shareholders' Equity	842.86	871.24	855.68	630.03	570.14	492
Total Liabilities & Equity	1,138	1,093	1,036	827.01	688.84	616.07

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	126.56	126.02	91.92	90.84	-	33.47
Net Cash (Debt)	51.66	64.2	362.48	210.19	263.43	142.28
Net Cash Growth	-82.18%	-82.29%	72.46%	-20.21%	85.15%	-20.78%
Net Cash Per Share	1.62	2.01	11.62	7.80	9.77	5.28
Filing Date Shares Outstanding	31.81	31.81	31.81	26.81	26.81	26.81
Total Common Shares Outstanding	31.81	31.81	31.81	26.81	26.81	26.81
Working Capital	10.43	84.59	418.66	245.99	190.68	127.89
Book Value Per Share	26.50	27.39	26.90	23.50	21.27	18.35
Tangible Book Value	842.13	870.47	853.75	628.95	568.46	491.76
Tangible Book Value Per Share	26.48	27.37	26.84	23.46	21.21	18.34
Land	127.19	127.19	127.19	127.19	127.19	199.16
Buildings	226.88	226.88	226.88	224.6	224.6	227.62
Machinery	49.45	47.53	47	41.18	41.55	43.05
Construction In Progress	440.92	392.07	58.96	-	-	0.83
Leasehold Improvements	3.14	3.14	2.75	1.06	0.63	0.63

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error